TABLE 4

Predicted human and observed human hepatic clearance for compounds with the potential for biliary excretion as the major clearance pathway

CompoundObserved CLHPredicted CLH Method 1Predicted CLH Method 2Observed CLH,intPredicted CLH,int Method 1Predicted CLH,int Method 2Reference for Observed Values
ml/min per kilogramml/min per kilogramml/min per kilogramml/min per kilogramml/min per kilogramml/min per kilogram
Lesinurad0.930.290.092100309.3Shen et al., 2015
Losartan7.54.10.7563021027Lo et al., 1995
PF-050897710.170.590.07912041053Jones et al., 2016
PF-051501223.21.20.98642016Jones et al., 2016
PF-051864621.30.120.013890748.0Jones et al., 2016
PF-052413285.70.0770.1059003951Jones et al., 2016
Pravastatin7.33.50.50347.90.83Singhvi et al., 1990
Rosuvastatin6.81.10.151107.50.95Martin et al., 2003
Valsartan0.350.0660.007185161.7Flesch et al., 1997
Disopyramide0.301.61.00.845.03.0Lima et al., 1984
Maraviroc7.23.92.730116.6Abel et al., 2008
Ranitidine2.62.13.23.62.84.4Chau et al., 1982; van Hecken et al., 1982
Zolmitriptan8.70.780.54211.10.73Dixon et al., 1997; Seaber et al., 1998
N13131313
AFE4.6116.416
bias0.340.120.250.080